Lymphangiosarcoma is a rare and aggressive cancer that develops in people who have experienced long-term swelling of the lymph nodes, most commonly in the arms following breast cancer treatment. Although modern surgical techniques have made this cancer much rarer than it once was, understanding its treatment options remains crucial for those affected by this serious condition.

Understanding Treatment Goals for Lymphangiosarcoma

Treatment for lymphangiosarcoma centers on removing the cancer as completely as possible while managing the complications that arise from this aggressive disease. Because this cancer spreads quickly to other parts of the body, particularly the lungs, early and decisive action is essential. The main goal is to stop the cancer from spreading and, when possible, extend survival time. However, it’s important to understand that lymphangiosarcoma carries a serious prognosis, with most patients surviving around two and a half years after diagnosis.^[1][2][3]

Treatment approaches depend heavily on whether the cancer has spread beyond its original location. When the tumor is still confined to one area, aggressive surgical removal offers the best chance for long-term survival. When the cancer has spread to distant parts of the body, treatment shifts toward controlling symptoms and slowing the disease’s progression. The high rate of recurrence means that even after successful initial treatment, patients require ongoing monitoring and may need additional therapy if the cancer returns.^[4]

The challenge with lymphangiosarcoma lies partly in how it develops. This cancer typically appears five to fifteen years after breast cancer treatment, specifically in patients who underwent classical radical mastectomy and developed severe, long-standing lymphedema. About ninety percent of cases occur in people with chronic lymphedema, making this swelling condition the primary risk factor. The cancer usually manifests as purple or bruised-looking areas on the swollen limb that progressively worsen into painful sores with tissue breakdown.^[5][6][7]

Standard Treatment Approaches

Surgical removal remains the cornerstone of lymphangiosarcoma treatment. The most successful approach, and often the most recommended by medical specialists, involves amputation of the affected limb. This may sound extreme, but given how quickly this cancer spreads and how difficult it is to completely remove through less aggressive surgery, amputation offers the best chance of eliminating all cancer cells and preventing spread to other organs. In some cases, particularly when the cancer affects the arm, surgeons may need to perform a forequarter amputation, which removes the entire arm along with the shoulder blade and part of the chest wall.^[1][8]

As an alternative to amputation, some patients may undergo wide local excision, where the surgeon removes the tumor along with a large margin of surrounding healthy tissue. This approach attempts to preserve the limb while still removing all visible cancer. However, the outcomes with wide local excision are generally less favorable than with amputation. The cancer tends to return locally, and there remains a significant risk that cancer cells have already spread through the lymphatic system or bloodstream to distant sites. Surgeons must remove not just the visible tumor but also the underlying subcutaneous tissue (the layer of tissue beneath the skin) and fascia (the connective tissue covering muscles) to ensure complete removal.^[9]

Even with early surgical treatment, the prognosis remains disappointing. The cancer has a high rate of local recurrence, meaning it often grows back in the same area, and it frequently metastasizes (spreads) to distant organs, particularly the lungs. When metastatic disease is present, surgery is generally not recommended unless it can provide symptom relief. In such cases, the focus shifts to palliative care rather than attempting to cure the disease.^[10]

Chemotherapy Options

Chemotherapy plays a supporting role in lymphangiosarcoma treatment. Unlike surgery, which directly removes the tumor, chemotherapy uses powerful drugs to kill cancer cells throughout the body. These medications are particularly important when there is evidence or suspicion that the cancer has spread beyond its original location. However, it’s crucial to understand that the effectiveness of chemotherapy for lymphangiosarcoma remains unclear in many cases due to the small number of patients studied and the variety of factors that influence outcomes.^[1]

Several chemotherapy drugs have shown some activity against lymphangiosarcoma. Paclitaxel is one agent that has been tried, with reports of questionable response when given weekly. This drug works by interfering with the cancer cells’ ability to divide and grow. Doxorubicin is another chemotherapy agent used against this cancer. It belongs to a class of drugs called anthracyclines and works by damaging the DNA inside cancer cells. Gemcitabine, which interferes with DNA synthesis, has also demonstrated some antitumor activity. Finally, ifosfamide, a drug that damages cancer cell DNA, rounds out the list of chemotherapy agents with evidence of activity against lymphangiosarcoma.^[1][9]

Chemotherapy is typically reserved for patients with inoperable disease, those with advanced cancer that has spread widely, or patients who refuse surgery. While some long-term survivors have been reported after chemotherapy treatment, the overall results have been discouraging compared to surgical approaches. The drugs can cause significant side effects, including nausea, hair loss, fatigue, increased infection risk due to lowered white blood cell counts, and potential damage to the heart or other organs depending on which agents are used.^[9]

Radiation Therapy and Other Approaches

Radiation therapy uses high-energy rays to kill cancer cells and shrink tumors. Like chemotherapy, it continues to be evaluated as an additional treatment alongside surgery for lymphangiosarcoma. Unfortunately, current evidence suggests that radiation therapy offers limited benefit for this particular cancer. Studies comparing patients treated with radiation therapy to those treated with chemotherapy have found no statistically significant difference in survival rates. While some long-term survivors after radiation therapy have been reported, these cases are exceptional rather than typical.^[9]

One innovative approach that has been explored involves hyperthermic isolated limb perfusion. This specialized technique involves temporarily isolating the blood flow to the affected limb and then perfusing it with heated chemotherapy drugs, specifically tumor necrosis factor-alpha and melphalan. The heat increases the effectiveness of the chemotherapy, and isolating the limb limits exposure of the rest of the body to these toxic drugs. When combined with radical surgical removal of the affected skin and subcutaneous tissue, including the fascia, this multimodal approach may provide enhanced survival compared to surgery alone. However, this is a highly specialized technique available only at certain medical centers.^[9]

Researchers have also explored immunotherapy for lymphangiosarcoma. One study from 1994 demonstrated that immunotherapy might provide palliative benefit for pleural effusions (fluid accumulation around the lungs) caused by metastatic angiosarcoma. Immunotherapy works by stimulating the body’s own immune system to recognize and attack cancer cells. However, this approach remains experimental for lymphangiosarcoma, and much more research is needed to determine its true value.^[9]

Emerging Treatments in Clinical Trials

Research into new treatments for lymphangiosarcoma continues, though the rarity of this cancer makes conducting large clinical trials challenging. Scientists are investigating several promising approaches that target specific molecular pathways involved in cancer growth and spread. These experimental treatments are being tested in clinical trials, which are carefully designed research studies that evaluate new therapies in human volunteers.^[9]

One area of investigation focuses on antilymphangiogenic therapy, which targets the formation of new lymphatic vessels. Researchers have discovered that lymphangiosarcoma tumors express high levels of a protein called VEGF-C (vascular endothelial growth factor C), which stimulates the growth of lymphatic vessels. This makes sense given that the cancer arises in the lymphatic system. By blocking VEGF-C or its receptors, scientists hope to starve the tumor of its ability to form the blood and lymphatic vessels it needs to grow and spread. This targeted approach represents a more precise way to attack the cancer compared to traditional chemotherapy, which affects all rapidly dividing cells in the body.^[9]

Another promising agent being studied is eribulin mesylate, a structurally modified analog of halichondrin B, a substance originally isolated from a marine sponge called Halichondria okadai. This drug works differently from traditional chemotherapy by targeting the microtubules that form the structural framework of cells. In one case report, eribulin mesylate successfully treated Stewart-Treves syndrome that had developed in the abdominal wall. While a single case report doesn’t prove effectiveness, it suggests this agent deserves further investigation in larger groups of patients.^[9]

Researchers are also exploring combinations of different treatment approaches. For example, one case involved treating lymphangiosarcoma of the lower limb with intra-arterial chemotherapy using mitoxantrone and paclitaxel. This technique delivers chemotherapy drugs directly into the artery supplying blood to the tumor, allowing much higher concentrations of the drugs to reach the cancer while limiting exposure to the rest of the body. The patient in this case had developed lymphangiosarcoma associated with chronic lymphedema following treatment for cervical cancer, demonstrating that this complication can occur after different types of cancer treatment.^[9]

The Importance of Prevention and Early Detection

Given the poor outcomes associated with lymphangiosarcoma, the most effective strategy is preventing it from developing in the first place. This means aggressive management of chronic lymphedema, the primary risk factor for this cancer. Patients who have undergone breast cancer treatment or other procedures that affect lymphatic drainage should work closely with their healthcare team to minimize and control lymphedema. This includes wearing compression garments, performing prescribed exercises, maintaining healthy weight, and promptly treating any infections in the affected limb.^[9]

Regular examination of lymphedematous areas is crucial for early detection. Any purple or bruised-looking areas, tender growths, or sores that don’t heal warrant immediate medical evaluation. Early biopsy of suspicious lesions can lead to earlier diagnosis, and earlier diagnosis combined with prompt surgical treatment offers the highest rate of long-term survival. The difference between catching the cancer early, when it’s still localized, versus after it has spread can be life or death.^[9]

Other complications commonly associated with chronic lymphedema must also be prevented and treated promptly. Erysipelas (a bacterial skin infection) and deep venous thromboses (blood clots in the deep veins) are both more common in lymphedematous limbs. Regular examination and early treatment of these conditions not only improves quality of life but may also reduce the risk of further complications, including possibly lymphangiosarcoma development.^[9]

Managing Complications and Advanced Disease

As lymphangiosarcoma progresses, particularly when it metastasizes to distant organs, managing complications becomes a central focus of care. The most common site of metastasis is the lungs, where cancer spread can cause shortness of breath, persistent cough, and pleural effusions (fluid accumulation in the space around the lungs). These complications may require hospitalization for drainage procedures or other interventions to help patients breathe more comfortably.^[9]

CT scans and other imaging tests can identify bilateral pulmonary involvement, meaning cancer in both lungs, which indicates advanced disease. At this stage, treatment focuses on palliative care—measures designed to improve quality of life and manage symptoms rather than cure the disease. Pain control becomes particularly important, as the cancer itself and its treatment can cause significant discomfort. Patients may need specialized pain management including strong medications, nerve blocks, or other interventions.^[9]

The emotional and psychological aspects of living with lymphangiosarcoma cannot be overlooked. The aggressive nature of this cancer, its poor prognosis, and the drastic treatments required (particularly amputation) create enormous stress for patients and their families. Support from mental health professionals, support groups, and palliative care teams can help patients and loved ones cope with the diagnosis and navigate the difficult decisions about treatment and end-of-life care.^[3]

Most common treatment methods

• Surgical removal
  • Amputation of the affected limb, which offers the best chance of long-term survival by completely removing all cancer tissue
  • Wide local excision as a limb-sparing alternative, removing the tumor with large margins of surrounding healthy tissue
  • Forequarter amputation for upper extremity involvement, removing the arm, shoulder blade, and part of the chest wall
  • Radical resection of affected skin and subcutaneous tissue including the fascia
• Chemotherapy
  • Paclitaxel, which interferes with cancer cell division
  • Doxorubicin, an anthracycline drug that damages cancer cell DNA
  • Gemcitabine, which interferes with DNA synthesis in cancer cells
  • Ifosfamide, which damages cancer cell DNA
  • Reserved for inoperable disease, advanced cancer, or patients who refuse surgery
• Radiation therapy
  • Uses high-energy rays to kill cancer cells and shrink tumors
  • Currently offers limited benefit based on available evidence
  • May be used as an adjunct to surgery in selected cases
• Advanced and experimental approaches
  • Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan combined with radical surgical resection
  • Intra-arterial chemotherapy with mitoxantrone and paclitaxel for localized delivery
  • Eribulin mesylate, a marine-derived compound that targets cellular microtubules
  • Immunotherapy for symptom control in metastatic disease
  • Antilymphangiogenic therapy targeting VEGF-C to prevent lymphatic vessel formation